Mochamad Iskandarsyah Agung Ramadhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mochamad Iskandarsyah Agung Ramadhan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ariadri Hafian Wulandaru Hakim
Department of Radiology, Pelita Harapan University, Tangerang, Indonesia
1 shared publication - Diatri Nari Lastri
Universitas Indonesia, Indonesia; Dr. Cipto Mangunkusumo Hospital, Indonesia
1 shared publication - Pukovisa Prawiroharjo
Department of Neurology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National Central Hospital, Jakarta, 10430, Indonesia
1 shared publication - Shierly Novitawati Sitanaya
Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia
1 shared publication - Yetty Ramli
Drs. Ramli, Rusdi, Kurniawan, and Evelyn are with the Department of Neurology, Faculty of Medicine, Universitas Indonesia in Jakarta, Indonesia
1 shared publication - Yetty Ramli
Department of Neurology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Dementia & Neuropsychologia
- Vol. 20
Cerebellar cognitive affective syndrome (Schmahmann syndrome) following isolated cerebellar infarction
The cerebellum plays an important role in higher-order cognition through cerebrocerebellar networks. Lesions affecting this structure may result in cerebellar cognitive affective syndrome (CCAS), which is frequently underrecognized by routine cognitive screening tools. We reported a 69-year-old right-handed man who presented with 18 months of forgetfulness, impaired concentration, and irritability following a documented left cerebellar infarction. Neurological examination revealed cerebellar signs without cortical deficits. Brain magnetic resonance imaging (MRI) demonstrated a left cerebellar infarct with hemorrhagic transformation. While the Mini-Mental State Examination (MMSE) was normal and the Montreal Cognitive Assessment (MoCA) showed mild impairment, detailed neuropsychological assessment using CCAS Scale (CCAS-S) confirmed definite CCAS. This case highlights the importance of cerebellum-specific cognitive assessment in patients with isolated cerebellar stroke, as conventional screening tools might underestimate multidomain cognitive and affective disturbances.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Dementia & Neuropsychologia
- Vol. 20
Open AccessCerebellar cognitive affective syndrome (Schmahmann syndrome) following isolated cerebellar infarction
The cerebellum plays an important role in higher-order cognition through cerebrocerebellar networks. Lesions affecting this structure may result in cerebellar cognitive affective syndrome (CCAS), which is frequently underrecognized by routine cognitive screening tools. We reported a 69-year-old right-handed man who presented with 18 months of forgetfulness, impaired concentration, and irritability following a documented left cerebellar infarction. Neurological examination revealed cerebellar signs without cortical deficits. Brain magnetic resonance imaging (MRI) demonstrated a left cerebellar infarct with hemorrhagic transformation. While the Mini-Mental State Examination (MMSE) was normal and the Montreal Cognitive Assessment (MoCA) showed mild impairment, detailed neuropsychological assessment using CCAS Scale (CCAS-S) confirmed definite CCAS. This case highlights the importance of cerebellum-specific cognitive assessment in patients with isolated cerebellar stroke, as conventional screening tools might underestimate multidomain cognitive and affective disturbances.
- Open Access
The Role of Iron-Chelating Therapy in Improving Neurological Outcome in Patients with Intracerebral Hemorrhage: Evidence-Based Case Report
Current primary intracerebral hemorrhage (ICH) treatments focus on limiting hematoma volume by lowering blood pressure, reversing anticoagulation, or hematoma evacuation. Nevertheless, there is no effective strategy to protect the brain from secondary injury due to ICH. Excess heme and iron as by-products of lysing clots in ICH might contribute to this secondary injury by triggering perihematomal edema. We present a clinical situation of an ICH case where iron-chelating therapy might be beneficial, as supported by scientific evidence. We looked through four databases (Pubmed, Cochrane, Embase, and Google Scholar) to find studies assessing the efficacy of iron-chelating therapy in ICH patients. Validity, importance, and applicability (VIA) of the included articles were appraised using worksheets from the Oxford Centre for Evidence-Based Medicine. Two out of five eligible studies were valid, important, and applicable to our patient. Both studies showed the positive effects of iron-chelating therapy on neurological outcome, as measured by National Institutes of Health Stroke Scale (NIHSS) score and modified Rankin Score (mRS). The beneficial effects of deferoxamine were demonstrated within the moderate volume (10–30 mL) subgroup, with a positive relative risk reduction (RRR) and low number needed to treat (six persons). Based on our appraisal, we considered iron-chelating therapy as an additional therapy for ICH patients, given its benefits and adverse effects. More specific studies using a larger sample size, focusing on moderate-volume ICH, and using standardized neurological outcomes are encouraged.
Open AccessThe Role of Iron-Chelating Therapy in Improving Neurological Outcome in Patients with Intracerebral Hemorrhage: Evidence-Based Case Report
Current primary intracerebral hemorrhage (ICH) treatments focus on limiting hematoma volume by lowering blood pressure, reversing anticoagulation, or hematoma evacuation. Nevertheless, there is no effective strategy to protect the brain from secondary injury due to ICH. Excess heme and iron as by-products of lysing clots in ICH might contribute to this secondary injury by triggering perihematomal edema. We present a clinical situation of an ICH case where iron-chelating therapy might be beneficial, as supported by scientific evidence. We looked through four databases (Pubmed, Cochrane, Embase, and Google Scholar) to find studies assessing the efficacy of iron-chelating therapy in ICH patients. Validity, importance, and applicability (VIA) of the included articles were appraised using worksheets from the Oxford Centre for Evidence-Based Medicine. Two out of five eligible studies were valid, important, and applicable to our patient. Both studies showed the positive effects of iron-chelating therapy on neurological outcome, as measured by National Institutes of Health Stroke Scale (NIHSS) score and modified Rankin Score (mRS). The beneficial effects of deferoxamine were demonstrated within the moderate volume (10–30 mL) subgroup, with a positive relative risk reduction (RRR) and low number needed to treat (six persons). Based on our appraisal, we considered iron-chelating therapy as an additional therapy for ICH patients, given its benefits and adverse effects. More specific studies using a larger sample size, focusing on moderate-volume ICH, and using standardized neurological outcomes are encouraged.